Back

Clinical and echocardiographic effects of vericiguat therapy in advanced heart failure patinets undergoing LVAD support

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 6 Ventricular Assist Devices HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Gregor Poglajen

University Medical Centre of Ljubljana, Ljubljana (Slovenia)

6 More presentations in this session

Presentation thumbnail
Histological profiling, viral analysis, and follow-up of inflammatory cardiomyopathy in adults supported by long-term left ventricular assist device therapy
Doctor M. Ruiz Cano (Bad Oeynhausen, DE)
Abstract Slides Video
Presentation thumbnail
The impact of sodium glucose transporter 2 inhibitors on cardiac remodeling in a large cohort of unselected patients
Doctor V. Copeland (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Warfarin and aspirin versus warfarin alone in patients with HeartMate 3 left ventricular assist device: a systematic review and meta-analysis.
Mr L. Rezende De Freitas (BR)
Abstract Slides Video
Presentation thumbnail
Impact of hemodynamic optimization on reducing pulmonary pressures and adverse clinical events in left ventricular assist device recipients with elevated pulmonary vascular resistance
Professor M. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Impact of an extended infectiological standard operating procedure on the outcome of patients with VAD-associated infections
Mr Y. Streef (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 6

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Temporal trends in the utilization of heart failure medical therapy in LVAD-supported advanced heart failure patients: a single center experience
thumbnail
Congress Presentation
Vericiguat in heart failure patients: analyzing safety, tolerability, and quality of life via meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Vericiguat in a real-world heart failure population: a single-centre experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources